Celcuity (CELC) is down roughly 3% in Tuesday trading (May 5, 2026), retreating from a rapid run-up that followed the company’s May 1 disclosure of positive topline Phase 3 VIKTORIA-1 results in the PIK3CA-mutant cohort for gedatolisib-based regimens. The May 1 8-K highlighted that the trial met its primary endpoint and pointed to a late-breaking ASCO presentation, which helped drive a momentum surge that is now being partially unwound.

There is no fresh, company-specific negative catalyst driving the decline; the move appears to be a classic digestion day after a large catalyst-driven jump. After the May 1 topline announcement and subsequent attention ahead of the 2026 ASCO Annual Meeting, traders are locking in gains and reducing exposure into the next headline windows, a dynamic that can be amplified in higher-volatility biotech names with crowded positioning.

Celcuity said detailed VIKTORIA-1 data will be presented in a late-breaking oral session at the 2026 ASCO Annual Meeting, scheduled for June 2, 2026. Separately, gedatolisib is already under Priority Review for HR+/HER2-/PIK3CA wild-type advanced breast cancer with a PDUFA goal date of July 17, 2026—two near-term events that can drive continued large swings in both directions depending on perceived efficacy, safety, and label breadth.

Celcuity has meaningful reported short interest, which can magnify both upside squeezes on positive news and pullbacks as momentum fades. With the stock still trading at an elevated level following the May 1 catalyst, near-term price action may continue to be driven more by positioning and event-risk management than by incremental fundamental updates until investors see the full ASCO dataset and get closer to the July FDA decision.